A novel inducible transactivation domain in the androgen receptor: implications for PRK in prostate cancer

Area of Science:

• Molecular Endocrinology
• Signal Transduction
• Cancer Biology

Background:

• Nuclear receptor activity, including the androgen receptor (AR), is regulated by both ligand-dependent and ligand-independent signaling pathways.
• Understanding these regulatory mechanisms is critical for developing effective cancer therapies, particularly for hormone-dependent cancers like prostate cancer.

Purpose of the Study:

• To identify and characterize a novel signal transduction pathway regulating androgen receptor (AR) transcriptional activity.
• To investigate the role of PRK1 in AR activation and its potential implications in prostate cancer.

Main Methods:

• In vivo and in vitro interaction studies between AR and PRK1.
• Functional assays to assess PRK1-mediated AR activation, including studies with different AR domains (TAU-5) and co-activators (TIF-2).
• Experiments evaluating AR activity under conditions mimicking prostate cancer treatment (adrenal androgens, AR antagonists).

Main Results:

• A novel pathway linking PRK1 to AR transcriptional activation was identified.
• PRK1 stimulation leads to ligand-dependent superactivation of AR.
• AR and PRK1 interact physically, and PRK1 activates AR via the TAU-5 domain.
• PRK1 promotes the formation of a functional AR-TIF-2 complex.
• PRK1 activates AR even in the presence of adrenal androgens and the AR antagonist cyproterone acetate.

Conclusions:

• PRK1 represents a novel regulator of AR transcriptional activity through a ligand-independent signaling pathway.
• The PRK1-AR signaling axis is active even under conditions of androgen ablation and antagonist treatment, suggesting its importance in prostate cancer.
• Overexpression of PRK1 in prostate tumors highlights its potential as a therapeutic target.